Novel Human Aminopeptidase N Inhibitors: Discovery and Optimization of Subsite Binding Interactions
Jisook Lee,Natalie B. Vinh,Nyssa Drinkwater,Wei Yang,Komagal Kannan Sivaraman,Luke S. Schembri,Michelle Gazdik,Peter M. Grin,Georgina S. Butler,Christopher M. Overall,Susan A. Charman,Sheena McGowan,Peter J. Scammells
DOI: https://doi.org/10.1021/acs.jmedchem.9b00757
IF: 8.039
2019-01-01
Journal of Medicinal Chemistry
Abstract:Aminopeptidase N (APN/CD13) is a zinc-dependent M1 aminopeptidase that contributes to cancer progression by promoting angiogenesis, metastasis, and tumor invasion. We have previously identified hydroxamic acid-containing analogues that are potent inhibitors of the APN homologue from the malarial parasite Plasmodium falciparum M1 aminopeptidase (PfA-M1). Herein, we describe the rationale that underpins the repurposing of PfA-MI inhibitors as novel APN inhibitors. A series of novel hydroxamic acid analogues were developed using a structure-based design approach and evaluated their inhibition activities against APN. N-(2-(Hydroxyamino)-2-oxo-1-(3',4',5'-trifluoro-[1,1'-biphenyl]-4-yOethyl)-4(methylsulfonamido)benzamide (6ad) proved to be an extremely potent inhibitor of APN activity in vitro, selective against other zinc-dependent enzymes such as matrix metalloproteases, and possessed limited cytotoxicity against Ad293 cells and favorable physicochemical and metabolic stability properties. The combined results indicate that compound 6ad may be a useful lead for the development of anticancer agents.